Disease details

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01647880 (ClinicalTrials.gov)	July 2013	23/7/2012	MOdification of VIsual Outcomes After Optic Neuritis in CIS or MS by Gilenya (MOVING Study)	Phase II/III Study to Investigate the Effects of Fingolimod Versus Interferon Beta-1b on Visual Recovery After Optic Neuritis	Multiple Sclerosis	Drug: Verum arm receiving Gilenya®;Drug: Active Comparator receiving Extavia®	Charite University, Berlin, Germany	NeuroCure Clinical Research Center, Charite, Berlin	Terminated	18 Years	55 Years	All	15	Phase 2/Phase 3	Germany
2	EUCTR2011-004787-30-DE (EUCTR)	26/10/2012	13/07/2012	Modification of the visual outcome after optic neuritis in CIS or MS by Gilenya®	Modification of the visual outcome after optic neuritis in CIS or MS by Gilenya® - MOVING	Multiple sclerosis or clinically isolated syndrom;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Gilenya® Product Name: Gilenya® Product Code: Gilenya® INN or Proposed INN: Fingolimod Other descriptive name: FINGOLIMOD Trade Name: Extavia ® Product Name: Extavia ® Product Code: Extavia ® INN or Proposed INN: Interferon beta 1B Other descriptive name: INTERFERON BETA -1B	Charite Universitaetsmedizin Berlin	NULL	Not Recruiting			Female: yes Male: yes	88	Phase 3	Germany
3	EUCTR2011-001956-12-CZ (EUCTR)	25/05/2011	04/05/2011	Biological Efficacy of Interferon ß Therapy in Patients with Multiple Sclerosis	Monitoring of MxA mRNA Expression as a Marker of Rresponse to Interferon ß Therapy in Patients with Multiple Sclerosis.	To correlate bioactivity of IFNß reflected by level of MxA expression and clinical course of MS To measure expression of MxA protein in patients treated with IFNß depending on NAbs statusNAbs positive cohorts will be correlated NAbs titer with level of MxA expression, respectively if the MxA decrease is not preceding NAbs positivity. The MxA induction test will be tested.	Trade Name: Avonex ® Product Name: Avonex ® Product Code: EU/1/97/033/002 Trade Name: Betaferon ® Product Name: Betaferon ® Product Code: EU/1/95/003/005-010 Trade Name: Rebif 22® Product Name: Rebif 22® Product Code: EU/1/98/063/001-003 Trade Name: Rebif 44® Product Name: Rebif 44® Product Code: EU/1/98/063/004-006 Trade Name: Extavia ® Product Name: Extavia ® Product Code: EU/1/08/454/001-002, EU/1/08/454/005-007	University Hospital Motol	NULL	Not Recruiting			Female: yes Male: yes		Phase 4	Czech Republic